Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-
Response Clinical Pharmacology Study of study drug In Subjects With Stable
Coronary Artery Disease (PLASMA)

Sponsor: Anthera Pharmaceuticals

Investigator: David Brown, MD
Research Coordinator: Tonya Goldston, RN, BSN, CCRC

Designated Site: Medical City Dallas


The main purpose of the study is to test the effects of study drug on an enzyme, a special the enzyme secretory Phospholipase A2 (sPLA2) which appears to be an important factor in the development of atherosclerotic plaques. The study will also investigate the effects of study drug on biochemical markers of inflammation and blood lipids, specifically LDL or “bad cholesterol”, which are involved in the development of atherosclerosis and can be indicators of risk for heart attack and stroke.